Phenotyping breast cancer by MR metabolomics: unscrambling the metastatic potential and predicting response to treatment
- Prosjektnummer
- 46051400
- Ansvarlig person
- Beathe Sitter
- Institusjon
- NTNU, ISB
- Prosjektkategori
- Flerårig prosjekt 2011
- Helsekategori
- Cancer
- Forskningsaktivitet
- 5. Treatment Developement
Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts.
Mol Oncol 2013 Feb;7(1):130-42. Epub 2012 okt 23
PMID: 23142657
Glycerophosphocholine (GPC) is a poorly understood biomarker in breast cancer.
Proc Natl Acad Sci U S A 2012 Sep;109(38):E2506; author reply E2507. Epub 2012 jul 31
PMID: 22851771
Lactate and glycine-potential MR biomarkers of prognosis in estrogen receptor-positive breast cancers.
NMR Biomed 2012 Nov;25(11):1271-9. Epub 2012 mar 8
PMID: 22407957
Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.
NMR Biomed 2012 Sep;25(9):1033-42. Epub 2012 jan 26
PMID: 22279038
Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
BMC Cancer 2012;12():39. Epub 2012 jan 25
PMID: 22277092
Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling.
NMR Biomed 2012 Feb;25(2):369-78. Epub 2011 aug 8
PMID: 21823183
In vivo MRS of locally advanced breast cancer: characteristics related to negative or positive choline detection and early monitoring of treatment response.
MAGMA 2011 Dec;24(6):347-57. Epub 2011 sep 10
PMID: 21909791
Feasibility of MR metabolomics for immediate analysis of resection margins during breast cancer surgery
PLoS One. 2013
Laktat og glycin - mulige metabolske markører for brystkreftprognose, analysert med MR spektroskopi (MRS).
Høstmøtet Norsk Kirurgisk Forening 2012
CLASSIFICATION OF TUMOR AND NON-INVOLVED BREAST TISSUE USING HR-MAS MR SPECTROSCOPY.
XIII Chemometrics in Analytical Chemistry; 2012
MR metabolomics as a clinical tool for separating breast cancer and non-involved tissue.
ESMRMB 2012
Metabolic characterization of triple negative breast cancers.
ESMRMB 2012
Metabolic characterization of triple negative breast cancers.
Personalized Cancer Care 2012
HR MAS MRS studies of breast cancer biopsies for defining clinically relevant sub-groups.
National PhD Conference in Medical Imaging; 2012
Cancer tissue metabolomics.
Norwegian Society for magnetic resonance, 2012
Prospects of high-field MR spectroscopy and MR metabolomics.
MR Core Facility opening, 2012
MR metabolic characterization of locally advanced breast cancer
- Disputert:
- mars 2012
- Hovedveileder:
- Ingrid S. Gribbestad
Molecular and functional characterization of breast cancer through a combination of MR imaging, transcriptomics and metabolomics
- Disputert:
- januar 2012
- Hovedveileder:
- Ingrid S. Gribbestad
Characterization of breast cancer using MR metabolomics and gene expression analysis
- Disputert:
- oktober 2012
- Hovedveileder:
- Ingrid S. Gribbestad
- Tone Frost Bathen Forskningsgruppeleder
- Maria Dung Cao Prosjektleder
- Guro Giskeødegård Prosjektleder
- Tonje Husby Haukaas Doktorgradsstipendiat
- Leslie Euceda Wood Doktorgradsstipendiat
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Helse Midt-Norge RHF - Samarbeidsorganet og FFU